Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

IMW 2019 | Current frontline treatment for WM

Jorge Castillo and Ramon Garcia-Sanz • 14 Sep 2019

IMW 2019

Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Bendamustine BTK inhibitors Carfilzomib Cyclophosphamide Dexamethasone Ibrutinib Rituximab

Jorge Castillo, MD, from Dana-Farber Cancer Institute, Boston, MA, and Ramon Garcia-Sanz, MD, from University Hospital of Salamanca, Salamanca, Spain, discuss the current frontline treatments for Waldenström’s Macroglobulinemia (WM), from the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM

Jorge Castillo • 10 Dec 2023

Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM

Jorge Castillo • 10 Dec 2023

Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting

Jorge Castillo • 10 Dec 2023

Research updates in WM from ASH 2023

Jorge Castillo • 10 Dec 2023

WM: BTK inhibitors

Jorge Castillo et al. • 14 Sep 2019

Novel BTK inhibitors for Waldenström’s macroglobulinemia

Ramon Garcia-Sanz • 14 Jun 2018

Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma

Ramon Garcia-Sanz • 14 Jun 2018

Related Videos

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024